PHASE-II CLINICAL-TRIAL OF CARBOPLATIN IN CANINE TRANSITIONAL-CELL CARCINOMA OF THE URINARY-BLADDER

Fourteen dogs with histologically-confirmed transitional cell carcinom a (TCC) of the urinary bladder were treated with 300 mg/m(2) carboplat in every 3 weeks. Response to therapy was assessed with abdominal radi ography, double contrast cystography, urinary bladder ultrasonography and thoracic radiography before therapy and at 6-week intervals during therapy. Dogs were monitored for hematologic toxicity with a CBC and platelet count performed immediately before and 10 to 14 days after ca rboplatin treatment. Tumor responses included progressive disease in 1 1 dogs and stable disease in 1 dog. Two dogs were euthanized due to ca rboplatin toxicity before assessment of tumor response. Toxicity inclu ded thrombocytopenia with or without neutropenia in 7 dogs and gastroi ntestinal toxicity in 6 dogs, Carboplatin therapy was not beneficial i n the treatment of TCC in the 14 dogs in this study. Copyright (C) 199 7 by the American College of Veterinary Internal Medicine.